RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ligand Pharmaceuticals Stock

Ligand Pharmaceuticals EBIT 2024

Ligand Pharmaceuticals EBIT

24.24 M USD

Ticker

LGND

ISIN

US53220K5048

WKN

A1C9RN

In 2024, Ligand Pharmaceuticals's EBIT was 24.24 M USD, a 146.8% increase from the 9.82 M USD EBIT recorded in the previous year.

The Ligand Pharmaceuticals EBIT history

YEAREBIT (undefined USD)
2030e183.96
2029e143.08
2028e103.75
2027e78.32
2026e116.79
2025e88.5
2024e24.24
20239.82
20223
202178.9
20208.7
2019-5.7
2018163.7
201768.1
201644.9
201528.3
201420.7
201315.9
20121.2
20111.9
2010-9.7
20095.7
2008-25.3
2007-60.2
2006-78.1
2005-43.6
2004-15.4

Ligand Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Ligand Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Ligand Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Ligand Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Ligand Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Ligand Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Ligand Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Ligand Pharmaceuticals’s growth potential.

Ligand Pharmaceuticals Revenue, EBIT and net profit per share

DateLigand Pharmaceuticals RevenueLigand Pharmaceuticals EBITLigand Pharmaceuticals Net Income
2030e490.57 M undefined183.96 M undefined0 undefined
2029e361.64 M undefined143.08 M undefined0 undefined
2028e296.42 M undefined103.75 M undefined0 undefined
2027e240.99 M undefined78.32 M undefined0 undefined
2026e225.99 M undefined116.79 M undefined137.34 M undefined
2025e185.48 M undefined88.5 M undefined116.44 M undefined
2024e156.78 M undefined24.24 M undefined100.5 M undefined
2023131.31 M undefined9.82 M undefined52.15 M undefined
2022196.2 M undefined3 M undefined-33.4 M undefined
2021277.1 M undefined78.9 M undefined57.1 M undefined
2020186.4 M undefined8.7 M undefined-3 M undefined
2019120.3 M undefined-5.7 M undefined629.3 M undefined
2018251.5 M undefined163.7 M undefined143.3 M undefined
2017141.1 M undefined68.1 M undefined12.6 M undefined
2016109 M undefined44.9 M undefined-1.6 M undefined
201571.9 M undefined28.3 M undefined229.8 M undefined
201464.5 M undefined20.7 M undefined12 M undefined
201349 M undefined15.9 M undefined11.4 M undefined
201231.4 M undefined1.2 M undefined-500,000 undefined
201130 M undefined1.9 M undefined9.7 M undefined
201023.5 M undefined-9.7 M undefined-10.4 M undefined
200938.9 M undefined5.7 M undefined-1.9 M undefined
200827.3 M undefined-25.3 M undefined-98.1 M undefined
200712.9 M undefined-60.2 M undefined281.7 M undefined
20064 M undefined-78.1 M undefined-31.7 M undefined
200510.2 M undefined-43.6 M undefined-36.4 M undefined
2004112.1 M undefined-15.4 M undefined-45.2 M undefined

Ligand Pharmaceuticals stock margins

The Ligand Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ligand Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ligand Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Ligand Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Ligand Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Ligand Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Ligand Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Ligand Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Ligand Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Ligand Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Ligand Pharmaceuticals Margin History

Ligand Pharmaceuticals Gross marginLigand Pharmaceuticals Profit marginLigand Pharmaceuticals EBIT marginLigand Pharmaceuticals Profit margin
2030e91.99 %37.5 %0 %
2029e91.99 %39.56 %0 %
2028e91.99 %35 %0 %
2027e91.99 %32.5 %0 %
2026e91.99 %51.68 %60.77 %
2025e91.99 %47.72 %62.78 %
2024e91.99 %15.46 %64.11 %
202391.99 %7.48 %39.72 %
202273.09 %1.53 %-17.02 %
202177.59 %28.47 %20.61 %
202083.69 %4.67 %-1.61 %
201990.52 %-4.74 %523.11 %
201897.46 %65.09 %56.98 %
201796.17 %48.26 %8.93 %
201694.86 %41.19 %-1.47 %
201591.93 %39.36 %319.61 %
201485.89 %32.09 %18.6 %
201388.16 %32.45 %23.27 %
201288.54 %3.82 %-1.59 %
201183.67 %6.33 %32.33 %
2010100 %-41.28 %-44.26 %
2009100 %14.65 %-4.88 %
200891.99 %-92.67 %-359.34 %
200791.99 %-466.67 %2,183.72 %
200691.99 %-1,952.5 %-792.5 %
200591.99 %-427.45 %-356.86 %
200483.68 %-13.74 %-40.32 %

Ligand Pharmaceuticals Aktienanalyse

What does Ligand Pharmaceuticals do?

Ligand Pharmaceuticals Inc is an American company that has been operating in the biotechnology industry for over 30 years. It was founded in 1987 in San Diego, California and has since built an impressive track record. The business model of Ligand Pharmaceuticals Inc is based on the development and commercialization of innovative drugs and technologies for the pharmaceutical and biotechnology industry. The company is a leading provider of resources for drug discovery and development, including ligand design, synthesis and analysis, tools for drug screening, and technologies for therapy optimization. Ligand Pharmaceuticals Inc is divided into several business segments that focus on different industries and categories of medication. These include oncology, immunology, neurology, metabolic diseases, and rare diseases. One of the key areas of Ligand Pharmaceuticals Inc is oncology, which focuses on the development of cancer drugs. The company currently has several innovative drugs in the pipeline targeting various types of cancer and showing promising results in clinical trials. Another important area of Ligand Pharmaceuticals Inc is immunology, which focuses on the development of drugs for autoimmune diseases. The company has some promising partnerships in this field, including one with Bristol Myers Squibb for the joint development of antibodies against the CTLA-4 receptor. In addition to drug development, Ligand Pharmaceuticals Inc also offers various technologies and tools for drug screening and therapy optimization. These include platforms for antibody and small molecule discovery, as well as technologies for antibody manufacturing and genome editing. Another important aspect of Ligand Pharmaceuticals Inc's business model is its partnership with other pharmaceutical companies. The company heavily relies on collaboration and currently has several strategic partnerships with some of the world's largest pharmaceutical companies. These partnerships allow Ligand to provide its partners with access to its technology and drug candidates, thereby expanding its portfolio. Over the years, Ligand Pharmaceuticals Inc has brought many successful products and technologies to the market. Some of the most well-known and successful products include Kyprolis, a treatment for multiple myeloma, and Promacta, a medication for immune thrombocytopenia. Overall, Ligand Pharmaceuticals Inc has built an impressive track record and is now considered one of the leading providers of resources for drug discovery and development. The company continues to prioritize collaboration and innovation and will undoubtedly bring many more innovative products and technologies to the market in the future. Ligand Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Ligand Pharmaceuticals's EBIT

Ligand Pharmaceuticals's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Ligand Pharmaceuticals's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Ligand Pharmaceuticals's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Ligand Pharmaceuticals’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Ligand Pharmaceuticals stock

How much did Ligand Pharmaceuticals achieve in EBIT for the current year?

In the current year, Ligand Pharmaceuticals has achieved an EBIT of 24.24 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Ligand Pharmaceuticals.

How has the EBIT of Ligand Pharmaceuticals developed in recent years?

The EBIT of Ligand Pharmaceuticals has increased by 146.798% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Ligand Pharmaceuticals?

The EBIT of Ligand Pharmaceuticals is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Ligand Pharmaceuticals pay?

Over the past 12 months, Ligand Pharmaceuticals paid a dividend of 15 USD . This corresponds to a dividend yield of about 14.55 %. For the coming 12 months, Ligand Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Ligand Pharmaceuticals?

The current dividend yield of Ligand Pharmaceuticals is 14.55 %.

When does Ligand Pharmaceuticals pay dividends?

Ligand Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ligand Pharmaceuticals?

Ligand Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Ligand Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ligand Pharmaceuticals located?

Ligand Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ligand Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ligand Pharmaceuticals from 4/19/2007 amounting to 2.5 USD, you needed to have the stock in your portfolio before the ex-date on 4/3/2007.

When did Ligand Pharmaceuticals pay the last dividend?

The last dividend was paid out on 4/19/2007.

What was the dividend of Ligand Pharmaceuticals in the year 2023?

In the year 2023, Ligand Pharmaceuticals distributed 0 USD as dividends.

In which currency does Ligand Pharmaceuticals pay out the dividend?

The dividends of Ligand Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Ligand Pharmaceuticals

Our stock analysis for Ligand Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ligand Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.